甲状腺機能検査市場ータイプ別(TSHテスト、T4テスト、T3テスト)、エンドユーザー別(病院、診断研究所、研究所)、および地域別ー世界的な予測2030年
PR TIMES / 2021年7月13日 8時45分
SDKI Inc.は、甲状腺機能検査市場の新レポートを2021年07月12日に発刊しました。この調査には、甲状腺機能検査市場の成長に必要な統計的および分析的アプローチが含まれています。レポートで提供される主要な産業の洞察は、市場の既存のシナリオに関する読者に市場の概要についてのより良いアイデアを提供します。さらに、レポートには、市場の成長に関連する現在および将来の市場動向に関する詳細な議論が含まれています。
レポートのサンプルURL
https://www.sdki.jp/sample-request-109432
[画像: https://prtimes.jp/i/72515/635/resize/d72515-635-f173ce28614308b5dfc3-1.png ]
The thyroid function testing market is estimated to grow from a market value of US $ 1.68 billion in 2022 to US $ 2.51 billion by 2030, with a CAGR of 5.9% during the forecast period. Market growth may be primarily due to factors such as an increased incidence of thyroid disorders, increased awareness of thyroid disorders, and an increased prevalence of lifestyle-related diseases. Increasing elderly population and increased consumption of alcohol and tobacco are also contributing to market growth. In addition, factors such as increased awareness of early screening of diseases and the existence of advanced diagnostic laboratories are also driving the growth of the thyroid function testing market. However, US adverse health care reforms could curb the growth of this market.
Market Segments The
thyroid function testing market is divided by type (TSH test, T4 test, T3 test), end user (hospital, diagnostic laboratory, laboratory), and region. These segments are further subsegmented based on a variety of factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
The hospital segment is projected to grow at a maximum CAGR during the forecast period.
Based on end users, the market is categorized into hospitals, diagnostic laboratories, laboratories, and other end users. The hospital segment is expected to grow at a maximum CAGR during the forecast period. Massive thyroid function tests performed in hospital-based laboratories around the world, increased patient numbers (and subsequent increases in the number of clinical tests performed in hospitals), and hospital-sponsored public medical awareness The increase in the number of campaigns is a driver of growth in this segment.
Regional overview
The Asia Pacific market is expected to grow at a maximum CAGR during the 2022-2030 forecast period. The high growth rate of this segment is due to the large elderly population, universal health insurance reimbursement policies, and the well-developed health care system in Japan. The high burden of thyroid disease, the increasing disposable income of China's middle-class population, and the presence of a large patient population are also several factors driving market growth. In addition, increased access to medical facilities and improved medical infrastructure in India are other major drivers of market growth in the region.
These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, Other Latin) USA); Middle East and Africa (Israel, GCC [Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy, Spain) , Hungary, Belgium, Netherlands, Luxembourg, NORDIC, Poland, Turkey, Russia and other Europe).
Major key players on the market
Key players in the thyroid function testing market include Thermo Fisher (USA), Abbott (USA), Roche (Switzerland), DiaSorin (Italy), Danaher (USA), Kronus (USA), Merck (Germany), Cortez Diagnostics. These include (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China). The study includes a detailed competitive analysis of these leading companies in the thyroid function testing market, company profiles, recent developments, and key market strategies.
Details of the survey report
https://www.sdki.jp/reports/thyroid-function-test-market/109432
SDKIInc. Company Profile
SDKI Inc.'s goals are Japan, China, the United States, Canada, the United Kingdom, Germany, etc. , Is to reveal the market scenarios of different countries. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With a trusted and customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.
企業プレスリリース詳細へ
PR TIMESトップへ
この記事に関連するニュース
-
エクイニクス、東京都心にAI対応データセンターTY15を9月に開設
PR TIMES / 2024年4月25日 17時40分
-
ICMG Nextが東京レインボープライド2024へ参加
PR TIMES / 2024年4月19日 16時40分
-
生産間接材購買プロセスDX革新「D-JIT(ディージット)」 をサービスイン<English Follows>
PR TIMES / 2024年4月15日 13時15分
-
"FIRST STAGE PRODUCTION EN" The 2nd Generation Male Talent Audition Open Now
PR TIMES / 2024年4月12日 17時45分
-
ランダム化比較試験でImpella CP(R)が心原性ショックを伴うST上昇型心筋梗塞患者の生存率を改善することを確認
PR TIMES / 2024年4月11日 15時45分
ランキング
-
1円上昇、一時151円台 3週間ぶり円高水準、介入警戒も
共同通信 / 2024年5月3日 22時28分
-
2過度な動き「ならす必要も」=円安、介入コメントせず―鈴木財務相
時事通信 / 2024年5月3日 23時51分
-
3日銀がこれほどまで円安を「無視」する3つの理由 「為替は管轄外」では、結局うまくいかない?
東洋経済オンライン / 2024年5月4日 8時30分
-
4いなば食品、大炎上も「ほぼ沈黙」の戦略的な是非 「沈黙は金」黙って耐える…のはもう通用しない
東洋経済オンライン / 2024年5月3日 19時30分
-
5黒田東彦・日銀前総裁「円安は一時的」…NYの講演で見解、マイナス金利解除・利上げは「当然のこと」
読売新聞 / 2024年5月3日 17時45分
記事ミッション中・・・
記事にリアクションする
記事ミッション中・・・
記事にリアクションする
エラーが発生しました
ページを再読み込みして
ください